Michael Wood - STERIS Plc Independent Director
| STE Stock | USD 225.47 0.20 0.09% |
Director
Dr. Michael B. Wood is Independent Director of the Company, since October 2004, and from August 2004 to the present a consultant orthopedic surgeon at the Mayo Clinic in Jacksonville, Florida and a Professor of Orthopedics at the Mayo Clinic College of Medicine. Dr. Wood served as President Emeritus of the Mayo Clinic Foundation from February 2003 until February 2004, and President and Chief Executive Officer of the Mayo Clinic Foundation from 1999 to 2003. The Mayo Clinic Foundation is a charitable, notforprofit organization based in Rochester, Minnesota, and is the parent corporate entity of the Mayo Clinics in Minnesota, Florida and Arizona. Dr. Wood served as a director of Cubist Pharmaceuticals, Inc. until June 2014.
| Age | 74 |
| Address | 5960 Heisley Road, Mentor, OH, United States, 44060 |
| Phone | 440 354 2600 |
| Web | https://www.steris.com |
Michael Wood Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Wood against STERIS Plc stock is an integral part of due diligence when investing in STERIS Plc. Michael Wood insider activity provides valuable insight into whether STERIS Plc is net buyers or sellers over its current business cycle. Note, STERIS Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell STERIS Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Wood over a year ago Acquisition by Michael Wood of 6154 shares of Team subject to Rule 16b-3 |
STERIS Plc Management Efficiency
The company has Return on Asset of 0.0559 % which means that on every $100 spent on assets, it made $0.0559 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0961 %, implying that it generated $0.0961 on every 100 dollars invested. STERIS Plc's management efficiency ratios could be used to measure how well STERIS Plc manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.08. The current year's Return On Capital Employed is expected to grow to 0.14. At present, STERIS Plc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.2 B, whereas Intangibles To Total Assets are forecasted to decline to 0.26.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Aimee Weisner | Glaukos Corp | 51 | |
| John Workman | CONMED | 69 | |
| Holly Sit | Penumbra | N/A | |
| Michelle Brennan | Masimo | 58 | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Bridget ORourke | Penumbra | 52 | |
| Rick Medlock | Smith Nephew SNATS | 60 | |
| Harpreet Grewal | Penumbra | 53 | |
| Ellen Zane | Boston Scientific Corp | 69 | |
| David Bronson | CONMED | 67 | |
| Don Kassing | Penumbra | 78 | |
| Bob White | Smith Nephew SNATS | 58 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Martha Aronson | CONMED | 53 | |
| Marc Stapley | Glaukos Corp | 50 | |
| William Summers | Integer Holdings Corp | 70 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Giovanni Caforio | Stryker | 56 | |
| Cheryl Blanchard | Anika Therapeutics | 61 | |
Management Performance
| Return On Equity | 0.0961 | ||||
| Return On Asset | 0.0559 |
STERIS plc Leadership Team
Elected by the shareholders, the STERIS Plc's board of directors comprises two types of representatives: STERIS Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STERIS. The board's role is to monitor STERIS Plc's management team and ensure that shareholders' interests are well served. STERIS Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STERIS Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Breeden, Independent Director | ||
| Daniel Carestio, Chief Operating Officer, Senior Vice President, Director | ||
| J Zangerle, Senior Vice President General Counsel, Secretary | ||
| Julia Madsen, Senior Sciences | ||
| Michael Wood, Independent Director | ||
| Andrew Xilas, Senior Dental | ||
| Julie Winter, Vice Communications | ||
| Michael Tokich, CFO, Principal Accounting Officer, Sr. VP and Treasurer | ||
| Karen Burton, CFO, Chief Accounting Officer, Vice President Controller | ||
| Paul Martin, Independent Director | ||
| John Zangerle, Senior Vice President General Counsel, Secretary | ||
| Kenneth Kohler, Senior AST | ||
| Jacqueline Kosecoff, Independent Director | ||
| Mary Fraser, SVP Officer | ||
| Cynthia Feldmann, Independent Director | ||
| Renato Tamaro, Vice President and Corporate Treasurer | ||
| Nirav Shah, Independent Director | ||
| Mohsen Sohi, Independent Chairman of the Board | ||
| Walter Rosebrough, CEO and President Director and Member of Compliance Committee | ||
| Richard Steeves, Independent Director | ||
| Loyal Wilson, Independent Director | ||
| Duncan Nichol, Independent Director | ||
| Christopher Holland, Independent Director | ||
| David Lewis, Independent Director | ||
| Cary Majors, Vice President - North America Commercial Operations |
STERIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STERIS Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0961 | ||||
| Return On Asset | 0.0559 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 24.6 B | ||||
| Shares Outstanding | 98.25 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 96.31 % | ||||
| Number Of Shares Shorted | 1.04 M | ||||
| Price To Earning | 36.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether STERIS plc is a strong investment it is important to analyze STERIS Plc's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact STERIS Plc's future performance. For an informed investment choice regarding STERIS Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STERIS plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade STERIS Stock refer to our How to Trade STERIS Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STERIS Plc. If investors know STERIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STERIS Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.238 | Dividend Share 2.18 | Earnings Share 6.21 | Revenue Per Share | Quarterly Revenue Growth 0.056 |
The market value of STERIS plc is measured differently than its book value, which is the value of STERIS that is recorded on the company's balance sheet. Investors also form their own opinion of STERIS Plc's value that differs from its market value or its book value, called intrinsic value, which is STERIS Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STERIS Plc's market value can be influenced by many factors that don't directly affect STERIS Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STERIS Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if STERIS Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STERIS Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.